Klinische Monatsblätter für Augenheilkunde, Journal Year: 2024, Volume and Issue: 241(09), P. 1021 - 1022
Published: Sept. 1, 2024
JAMA Ophthalmology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 20, 2025
Importance Semaglutide, a glucagonlike peptide-1 receptor agonist (GLP-1RA), has recently been implicated in cases of nonarteritic anterior ischemic optic neuropathy (NAION), raising safety concerns the treatment type 2 diabetes (T2D). Objective To investigate potential association between semaglutide and NAION Observational Health Data Sciences Informatics (OHDSI) network. Design, Setting, Participants This was retrospective study across 14 databases (6 administrative claims 8 electronic health records). Included were adults with T2D taking semaglutide, other GLP-1RA (dulaglutide, exenatide), or non–GLP-1RA medications (empagliflozin, sitagliptin, glipizide) from December 1, 2017, to 31, 2023. The incidence proportion rate calculated. Association assessed using approaches: an active-comparator cohort design comparing new users those GLP-1RAs drugs, self-controlled case-series (SCCS) analysis compare individuals’ risks during exposure nonexposure periods for each drug. used propensity score–adjusted Cox proportional hazards models estimate hazard ratios (HRs). SCCS conditional Poisson regression (IRRs). Network-wide HR IRR estimates generated random-effects meta-analysis model. Exposures non–GLP-1RAs. Main Outcomes Measures under alternative definitions based on diagnosis codes: one more inclusive sensitive, restrictive specific. Results included 37.1 million individuals T2D, including 810 390 users. Of 43 620 Optum’s deidentified Clinformatics Mart Database, 24 473 (56%) aged 50 69 years, 26 699 (61%) female. 14.5 per 100 000 person-years among not different compared that non–GLP-1RAs sensitive definition—empagliflozin (HR, 1.44; 95% CI, 0.78-2.68; P = .12), sitagliptin 1.30; 0.56-3.01; .27), glipizide 1.23; 0.66-2.28; .25). risk higher only patients empagliflozin 2.27; 1.16-4.46; .02) specific definition. showed increased (meta-analysis IRR, 1.32; 1.14-1.54; < .001). Conclusions Relevance this suggest modest increase associated use, smaller than previously reported, warranting further investigation into clinical implications association.
Language: Английский
Citations
7
JAMA Ophthalmology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 30, 2025
Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Ophthalmology HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals Network Open Cardiology Dermatology Health Forum Internal Medicine Neurology Oncology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy Accessibility Statement 2025 American Medical Association. All Rights Reserved Search Archive Input Term Sign In Individual inCreate an Account Access through institution Purchase Options: Buy this article Rent Subscribe the journal
Language: Английский
Citations
2
Eye, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 15, 2025
Language: Английский
Citations
2
Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown
Published: March 17, 2025
Abstract Aims To investigate the putative association between semaglutide and non‐arteritic anterior ischaemic optic neuropathy (NAION). Materials Methods Data from national health registries in Denmark (2018–2024) Norway (2018–2022) were used to compare NAION risk individuals with type 2 diabetes initiating versus sodium‐glucose co‐transporter inhibitors (SGLT‐2is). A supplementary self‐controlled analysis examined among all users. National estimates pooled using a fixed‐effects model. Results We identified 44 517 users of for management 16 860 Norway, total 32 events observed. The unadjusted incidence rate was 2.19/10 000 person‐years Danish initiators, compared 1.18 SGLT‐2i initiators. In corresponding rates 2.90 0.92, respectively. After adjustment, hazard ratio (HR) 2.81 (95% confidence interval [CI] 1.67–4.75), difference (IRD) +1.41 CI +0.53 +2.29) per 10 person‐years. Estimates consistent across both countries but higher less precise (HR 7.25; 95% 2.34–22.4) 2.17; 1.20–3.92). remained sensitivity analyses, stronger observed post hoc per‐protocol 6.35; 2.88–14.0). study, symmetry ratios (SRs) 1.14 0.55–2.36) 2.67 0.91–8.99) Norway. Conclusions use managing is associated an increased SGLT‐2is. However, absolute remains low.
Language: Английский
Citations
2
medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 11, 2024
Abstract Importance Recent findings have raised concerns about an association between semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), and non-arteritic anterior ischemic optic neuropathy (NAION). Objective To further investigate the putative semaglutide use NAION. Design Bi-national active comparator new-user cohort study with propensity score weighing to adjust for confounding, fixed-effect meta-analysis, supplementary self-controlled analysis (symmetry analysis). Setting Data were obtained from national health registries in Denmark Norway, including prescription registries, patient civil registration systems. Participants New users of sodium-glucose co-transporter 2 inhibitors (SGLT-2is) during 2018-2022 (Norway) 2018-2024 (Denmark). Exposures Initiation SGLT-2is management type diabetes was assessed main analysis. In design, exposure regardless indication, investigated. Main Outcomes Measures Incidence rates NAION among users, along hazard ratios (HRs) incidence rate differences (IRDs) robust 95% confidence intervals. Estimates Norway pooled using fixed-effects model (inverse variance weighting). The returned sequence symmetry (SRs). Results We identified 44,517 eligible 16,860 Norway. total, we observed 32 events (24 8 Norway). This yielded unadjusted 2.19/10,000 person-years Danish initiators, compared 1.18 SGLT-2i initiators. corresponding 2.90 0.92. After adjustment, HR 2.81 (95% CI 1.67 4.75) IRD +1.41 +0.53 +2.29). compatible individual countries, although higher less precise estimates (HR 7.25; 2.34 22.4) 2.17; 1.20 3.92). consistent across sensitivity analysis, notably stronger post hoc per-protocol 6.35; 2.88 14.0). study, SRs 1.14 0.55 2.36) 2.67 0.91 8.99) Conclusions Relevance Our show risk However, absolute remains low. Key Points Question Is there (NAION)? Findings this conducted associated increased NAION; ratio interval (CI) difference (absolute increase) +2.29) per 10,000 person-years. finding Meaning confirms that is NAION, but also excess
Language: Английский
Citations
6
JAMA Ophthalmology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 20, 2025
Language: Английский
Citations
0
JAMA Ophthalmology, Journal Year: 2025, Volume and Issue: unknown
Published: March 27, 2025
Language: Английский
Citations
0
Current Opinion in Ophthalmology, Journal Year: 2025, Volume and Issue: unknown
Published: March 27, 2025
Purpose of review Glucagon-like peptide-1 receptor agonists (GLP-1RA) have gained popularity as an antidiabetic and weight loss agent with protective cardiovascular outcomes, but attention to the potential ocular side effects has grown. This aims consolidate existing evidence on GLP-1RA conditions such diabetic retinopathy (DR), nonarteritic ischemic optic neuropathy (NAION), glaucoma, age-related macular degeneration (AMD), idiopathic intracranial hypertension (IIH), dry eye disease (DED). Recent findings The effect DR is controversial likely linked rapid correction hemoglobin A1c levels. may be associated increased risk NAION, although mechanism remains elusive. Protective been shown against AMD, DED possibly due its anti-inflammatory properties, these medications decrease pressure in IIH. Summary As usage increases, further dedicated safety trials are key determining eye-related complications. Given limited prospective available proven systemic benefits medication, well certain diseases, use should generally not discouraged most patients. Regular ophthalmologic follow up important patients considered at higher adverse events.
Language: Английский
Citations
0
European Journal of Ophthalmology, Journal Year: 2025, Volume and Issue: unknown
Published: April 4, 2025
Introduction The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as Semaglutide, have revolutionized the treatment of type 2 diabetes mellitus and obesity. Case desciption aim present study was to report a case Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) occurring in diabetic patient taking Semaglutide review literature order find possible relation between ophthalmological event drug intake. Discussion Although clinical trials did not any significant increase risk NAION, recent retrospective cohort suggested association NAION GLP-1 RAs. After this publication, became an hot topic several studies were published, presenting conflicting results. Conclusion Importance Albeit use RAs date, remain controversial, clinicians ophthalmologists should be aware analyze for each risk-benefit ratio.
Language: Английский
Citations
0
Journal of Diabetes, Journal Year: 2025, Volume and Issue: 17(4)
Published: April 1, 2025
Language: Английский
Citations
0